🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Is it time for neoadjuvant before radical prostatectomy? 💊💉ARNEO: Degarelix with/Without Apalutamide Prior to RP for High-risk #ProstateCancer 🔶Minimal residual disease:DA 38%🆚D 9.1%, no pCR 🔶PTEN loss lesses MRD 11%🆚43% 🔶PROTEUS trial awaited OncoAlert European Association of Urology (EAU) ASCO

and link for article: doi.org/10.1016/j.euru…

ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer buff.ly/3dMB7rB Gaëtan Devos steven joniau Van Poppel Hendrik Gert De Meerleer

Great job¡¡¡ Congrats to the UH Leuven...steps to a new therapeutic scenario in HR PCa...steven joniau Gaëtan Devos Gert De Meerleer Wouter Everaerts Hein Van Poppel Lorenzo Tosco,Carl Van Haute et al

Great achievement by Gaëtan Devos and the entire steven joniau led KU Leuven group, this paper in European Urology Looking forward to the follow-up projects 💥 sciencedirect.com/science/articl…

Neoadjuvant degarelix plus apalutamide results ina more favorable pathological outcome when compared with degarelix alone before #radicalprostatectomy. Read more 👇 prostate.uroonco.uroweb.org/publication/ar… Gaëtan Devos steven joniau Yannic Raskin Van Poppel Hendrik Gert De Meerleer Roderick van den Bergh #prostatecancer

💥 Congratulations to dr. Gaëtan Devos for completing his PhD. with an excellent public defense KU Leuven

Impressive PhD defense yesterday from Gaëtan Devos exploring high-risk and oligometastatic prostate cancer, with rightly proud promotors steven joniau Wouter Everaerts Gert De Meerleer. Great honour to be in the jury with Alberto Briganti, tombal, Prof Claessens and Prof Durmez.

Excellent dinner after impressive PhD thesis by Gaetan Devos. High-risk prostate cancer and clear evidence in metastasis-directed therapy. Happy to be part of this team. #respect #prostatecancer #SBRT #arneo #oligo ⁦steven joniau⁩ ⁦Hein Van Poppel⁩ ⁦tombal⁩

Excellent PhD defense by Gaetan Devos. New treatment options in high-risk prostate cancer and a new proof of the power of metastatis-directed therapy in oligometastatic prostate cancer. Proud to be copromotor 🙏 #respect #prostate #cancer #SBRT #oligo ⁦steven joniau⁩ ⁦

Very proud promotor of Gaëtan Devos, who defended his PhD last Friday. Great conclusions and a new adagio: “Eat, sleep, MDT, repeat”. Co-promotors Gert De Meerleer & Wouter Everaerts. Jury Alberto Briganti, tombal, Pieter Uvin, prof Claessens and prof Dumez

Congratulations to Gaëtan Devos for defending his PhD last week🎓👏!

Proud to present our article in European Urology Oncology: Predictors of recurrence after MDT in oligometastatic prostateCa. Free version below. authors.elsevier.com/a/1ghXV9Cfv-xp… Thanks to steven joniau Gert De Meerleer Charlien Berghen @J_Kuijk Eduard Roussel Gaëtan Devos Thomas VdB Thomas VandenBroeck

Great presentation of #ARNEO results by steven joniau #UroOnco23 Neoadjuvant treatment apa/ADT vs ADT prior to RP in #prostatecancer: BCR not sign. different yet + MRD does not seem to be a good surrogate for BCR. But: downstaging to pT2 was higher with apa/ADT + correlated with BCR

Nice work by Karel David ! Three months of neoadjuvant ADT in high-risk PCa patients results in early bone loss. These findings underscore the importance for bone health prevention in men treated with ADT . European Association of Urology (EAU) UZ Leuven

The last day of the #BAU2023 congress is being kicked off with an interesting #ProstateCancer case, presented by Gaëtan Devos and moderated by steven joniau Julien Van Damme! Please find the programme on our website 👇 Société Belge d'Urologie European Association of Urology (EAU) ESRU Belgium bau.be/programme/

Één van mijn mentoren steven joniau Erg toffe mens, uitstekende wetenschapper en dito chirurg. Veel van geleerd en nog veel van aan het leren 🙂 nieuwsblad.be/cnt/dmf2023112…

Today we presented the 3 year oncological outcomes of the ARNEO trial: - Patients treated with 3 mo neoadjuvant ADT + Apalutamide have tendency towards improved BCR free and metastasis free survival. - pT2 disease associated with less biochemical recurrence. steven joniau Alexander Giesen

Congratulations again to #ARNEO study Gaëtan Devos steven joniau Alexander Giesen ▶️MRD doesn't predict BCR ▶️We will need to wait for a possible significant impact on MFS with longer FU ▶️ypT stage correlates with outcomes 👉 Did downstaging after neoadjuvant treatment correlate with BCR?

ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer by Gaëtan Devos et al Full article: europeanurology.com/article/S0302-…